82059-50-5

Usage

Uses

Treatment of irritable bowel syndrome, Crohn’s disease; anti-anxiety, anti-stress.

InChI:InChI=1/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3/t15-/m0/s1

Upstream product

• 22345-47-7 tofisopam 

Relevant academic research and scientific papers

Method of lowering serum uric acid levels with (S)-tofisopam

Enantiomerically-pure (S)-tofisopam is administered to lower serum uric acid levels in a mammal.

Phosphodiesterase inhibitors

The invention relates especially to novel stereospecific derivatives of 2,3-benzodiazepine type as inhibitors of phosphodiesterases, especially 2 and 4, and uses thereof in the therapeutic field, most particularly for preventing and treating pathologies involving a central and/or peripheral disorder. The compounds of the invention more particularly correspond to the general formulae (I) and (II):

USE OF TOFISOPAM AS A PDE10A INHIBITOR

The present invention relates to a novel use of Tofisopam for the preparation of a pharmaceutical composition made for treatment of the positivsymptoms and cognitive deficits in schizophrenic patients.

Conversion process for 2,3-benzodiazepine enantiomers

Methods for the racemization of an enantiomer of a 2,3-benzodiazepine molecule into the corresponding racemic mixture under either basic or acidic conditions are described. Furthermore, the invention relates to the conversion of an enantiomer of tofisopam or its metabolites to the corresponding opposite enantiomer.

Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammels.

Treatment of inflammatory disorders with 2,3- benzodiazepines

Compounds according to formula I: 1 wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders, particularly inflammatory disorders mediated by LTB4,

Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

Compounds according to formula I: 1wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders mediated by LTB4,

Method of increasing neutrophil production using 2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammals.

Method for isolating (R)-tofisopam

(R)-tofisopam, substantially free of the (S)-enantiomer of tofisopam, is obtained by separating the enantiomers of tofisopam by chromatography employing a chiral separation medium comprising (i) (2S)-2-{(1S)[(3,5-dinitrophenyl)carbonylamino]phenylmethyl}-